First Quarter 2018

cryoport

SCIENCE. LOGISTICS. CERTAINTY.

Trusted by the Life Sciences Industry

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Safe Harbor – Forward Looking Statements

This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans regarding partnering activities, product pricing, financial forecasts. Such statements are only predictions and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that the Company may not be able to identify acceptable strategic opportunities or conclude any strategic transaction which it does identify, the risk that products that appeared promising in early use do not demonstrate the same utility in larger-scale uses, the risks associated with the Company's reliance on outside financing to meet its capital requirements, and the risks associated with the Company's reliance on collaborative partners for shipping. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. These factors and others are more fully discussed in the Company's periodic reports and other filings with the Securities and Exchange Commission.

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Financial Highlights: Q1-2018

Revenue
$4.0M
up 48.3%

Biopharma revenue
up 62.3%

31 Phase III trials

Supporting 236 clinical trials

GPS TRACKING

24 biopharma clients added during the quarter

Reproductive Medicine
up 20.1%

Gross Margin
54.3%
up 8.1PP

GLOBAL FACILITY FOOTPRINT

Strong embedded growth with existing clients

1 BEST IN CLASS FLEET PERFORMANCE

Opex up 31.8% in support of expected growth

$19M Cash
No debt

Adjusted EBITDA improved by 37.1% to ($0.5M)

27.6M share o/s
EPS ($0.10)

All comparisons are on a year-over-year basis

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Novartis – Kymriah™ Ramp Continues

35 certified treatment centers
$12 million Q1 2018 revenue for Novartis
Manufactured for over 300 patients in 11 countries
Over 500 employees supporting Kymriah™

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Gilead – Yescarta ramp builds

- Yescarta approved in U.S. in October 2017
- European approval anticipated in Q3 2018
- 40 cancer centers authorized as of April 30, 2018
  - Expanding number of authorized centers and by mid-2018 reaching institutions responsible for treating ~80%of eligible patients
- Access and reimbursement consistent with pre-launch expectations for new therapies in inpatient hospital setting
- $40 million in Net Product Revenues in Q1 2018
- Cell Design Labs acquisition brings expertise in synthetic biology
- Sangamo collaboration provides access to zinc finger nuclease genome editing technology for the potential development of allogeneic and other genetically modified cell therapies for cancer

Kite
A GILEAD Company

YESCARTA™
(axicabtagene ciloleucel) Suspension for IV infusion

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Clinical Trials Drive Revenue Growth in Biopharma

22 new clinical trials (net) added in Q1-2018; 97 clinical trials (net) added since Q1-2017; 31 Phase III



cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Adaptive Cellular Therapy :: Immuno-Oncology Landscape



Source – Wells Fargo Securities Conference, November 2017

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Primary Target Market: Regenerative Therapy

959

Clinical trials underway [(a)]

804 year-end 2016 [(b)]
631 year-end 2015 [(b)]

Ph. I: 320

(261 in 2016)
(192 in 2015)

Ph. II: 549

(376 in 2016)

(376 in 2015)

Ph. III: 90

(68 in 2016)
(63 in 2015)

- **Inflection point: Commercialization has begun**
- **Novartis' CAR-T drug, Kymriah™, approved in August 2017 and Gilead/Kite therapy, Yescarta™, approved in October 2017**
- **At least 5-7 additional BLA/EMAs for regenerative therapies expected in 2018**
- **861 companies globally in the Regenerative Therapy Market**
- **Total of 14 Regenerative Medicine Advanced Therapy designations granted.**

(a) Alliance for Regenerative Medicine, April 17, 2018
(b) Alliance for Regenerative Medicine, March 7, 2017

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Cryoport Express® C3™ Shipper for Clients Requiring Reliable 2-8°C Logistics Solutions

The introduction of Cryoport Express® C3™ means that Cryoport supports the entire logistics continuum for regenerative medicine clinical and commercial programs

- The Cryoport Express® C3™ Solution seamlessly integrates Cryoport's expertise in packaging, informatics and logistics for life science commodities requiring 2-8°C temperatures
- Cryoport's powerful Cryoportal™ Logistics Management Platform and leading-edge SmartPak II™ Condition Monitoring System provide visibility of the location and the key aspects of your critical shipment
- 24/7/365 Customer Service support to proactively monitor shipment and mitigate risk with automated escalation
- Launched in August 2017



cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Cryoport's Continuous Vigilance to Minimize Risk and Maximize Success

CHAIN of CUSTODY ○ **CHAIN of CONDITION** ○ **CHAIN of IDENTITY** ○ **CHAIN of COMPLIANCE**



Traceability of each Client's or Patient's Therapy	Traceability of the Environmental Controls of each Client's or Patient's Therapy	Traceability of the Identity of each Client's or Patient's Therapy	Traceability of the Equipment and Processes supporting each Client's or Patient's Therapy

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

CryoStork℠ for Reproductive Medicine

CryoStork℠

Science



Risk Mitigation

Quality by Design*

Over 50 proprietary modifications to shippers to maximize in-field performance

Logistics

Active Monitoring

24/7/365 Customer Support

Certainty

OVER 160,000 amount of shipments

62% of clinics in US using CryoStork service

OVER 7 years of IVF shippping experience

cryoport

SCIENCE. LOGISTICS. CERTAINTY.

Quarterly Revenue Trends

Continued quarterly revenue growth fueled by revenue expansion from existing clients and new client acquisition



cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Revenue Trends

Biopharma growth continues to be driven by ramp in clinical trials supported and commencement of revenue from the support of commercials therapy launches



cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Cryoport has a Scalable Business Model

Continuing double-digit growth in revenue, year-over-year and sequentially, further increases gross margin

Net revenue for Q1-2018 vs. prior year ($mm)



Gross margin % for Q1-2018 vs. prior year



cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Review

Business description	**Leading temperature-controlled logistics solutions provider for the life sciences industry with a focus on the regenerative medicine market (CAR-T)**
Clients	**Pharmaceutical and biotechnology companies (Novartis, Gilead/Kite[(a)], TiGenix, etc.)**
Markets	**Biopharma, Reproductive Medicine, and Animal Health**
Commercial Biopharma Agreements	**Novartis and Gilead/Kite**
Number of Clinical Trials Currently Supported	**236, 31 of which are in Phase III**
Revenue Growth Year-over-Year	**48%**
Q1 2018 Gross Margin	**54%**
Sequential Quarterly Revenue Growth	**21%**
CEO	**Jerrell Shelton**
Headquarters	**Irvine, CA**

(a) Kite was acquired by Gilead Sciences in October 2017

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Science. Logistics. Certainty.

Thank you!

cryoport
SCIENCE. LOGISTICS. CERTAINTY.